AMLX stock forecast for mid-2024 trends toward modest gains, with technical charts showing strong support levels around $18. Amylyx Pharmaceuticals certainly has been doing a good job lately as it's been growing revenue more than most other companies. Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour. This article is not financial advice. See Quiver Quantitative's disclaimers for more information. AMLX stock forecast sees benefit from strong cash position post recent capital raise, giving flexibility for R&D expenditure without near-term dilution pressure.